Airiau, Kelly
ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib. [electronic resource]
- Experimental hematology May 2012
- 367-78.e2 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
ISSN: 1873-2399
Standard No.: 10.1016/j.exphem.2012.01.004 doi
Subjects--Topical Terms: Antigens, CD34--analysis Antineoplastic Agents--pharmacology Apoptosis--drug effects Apoptosis Regulatory Proteins--physiology Bcl-2-Like Protein 11 Benzamides Biphenyl Compounds--pharmacology Cell Line, Tumor--drug effects Down-Regulation--drug effects Drug Resistance, Neoplasm--drug effects Drug Screening Assays, Antitumor Drug Synergism Gene Expression Regulation, Leukemic--drug effects Hematopoietic Stem Cells--drug effects High-Temperature Requirement A Serine Peptidase 2 Humans Imatinib Mesylate K562 Cells--drug effects Leukemia, Myelogenous, Chronic, BCR-ABL Positive--pathology Membrane Proteins--physiology Mitochondrial Proteins--physiology Neoplasm Proteins--biosynthesis Neoplastic Stem Cells--drug effects Nitrophenols--pharmacology Piperazines--pharmacology Protein Kinase Inhibitors--pharmacology Proto-Oncogene Proteins--physiology Proto-Oncogene Proteins c-bcl-2--antagonists & inhibitors Pyrimidines--pharmacology Serine Endopeptidases--physiology Sulfonamides--pharmacology X-Linked Inhibitor of Apoptosis Protein--biosynthesis